Elidel

Elidel is a brand name of pimecrolimus topical, approved by the FDA in the following formulation(s):

ELIDEL (pimecrolimus - cream; topical)

• 
  Manufacturer: VALEANT INTL
  
  Approval date: December 13, 2001
  
  Strength(s): 1% ^[RLD]

Has a generic version of Elidel been approved?

No. There is currently no therapeutically equivalent version of Elidel available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Elidel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Heteroatoms-containing tricyclic compounds
  Patent 5,912,238
  Issued: June 15, 1999
  Inventor(s): Baumann; Karl & Emmer; Gerhard
  Assignee(s): Novartis AG
  The invention concerns the compounds of formula I ##STR1## wherein the substituents have various significances. They are prepared by several processes including epimerizing replacement, treatment with cyanogen bromide or thiophosgene, treatment with an acid having a non-nucleophilic anion, treatment with dimethylsulfoxide and acetic anhydride, acylation, treatment with an oxalyl derivative and ammonia, methylation, oxidation, deprotection and protection. They possess interesting pharmacological activity as antiinflammatory, immunosuppressant, antiproliferative and chemotherapeutic drug resistance reversing agents.
  
  Patent expiration dates:
  
  
  • June 15, 2016
    
  
  
  
  • December 15, 2016
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical compositions
  Patent 6,352,998
  Issued: March 5, 2002
  Inventor(s): Martin; Jackman & Xue-Ping; Popp & Friedrich; Richter & Fritz; Schmook
  Assignee(s): Novartis AG
  This invention provides a topical composition, in the form of an emulsion, that comprises a compound of the FK506 class; a physiologically acceptable alkanediol, ether diol or diether alcohol containing up to 8 carbon atoms as solvent for the compound of the FK506 class; an unsaturated fatty alcohol and water. In another aspect, this invention provides a topical pharmaceutical composition that comprises a macrolide in suspension. In a further aspect, this invention provides the use of an unsaturated fatty alcohol to stabilize a macrolide in a pharmaceutical composition.
  
  Patent expiration dates:
  
  
  • October 26, 2015
    
  
  
  
  • April 26, 2016
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Crystalline macrolides and process for their preparation
  Patent 6,423,722
  Issued: July 23, 2002
  Inventor(s): Cornelia; Dosenbach & Maximilian; Grassberger & Otto; Hartmann & Amarylla; Horvath & Jean-Paul; Mutz & Gerhard; Penn & Sabine; Pfeffer & Dierk; Wieckhusen
  Assignee(s): Novartis AG
  33-Epichloro-33-desoxyascomycin of formula I and various tautomeric or forms thereof, in crystalline form, such as Form A and Form B. Their preparation involves appropriately converting amorphous compound of formula I, or compound of formula I in other than Form A, or compound of formula I in other than Form B, respectively, from a solution thereof under crystallization-inducing conditions or conditions inducing preferential crystallization of Form A or B, respectively. Such crystals are particularly indicated for use in the preparation of topical galenical forms of the compound for pharmaceutical use, e.g. creams, emulsions and ointments.
  
  Patent expiration dates:
  
  
  • June 26, 2018
    
  
  
  
  • December 26, 2018
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Elidel Consumer Information (Drugs.com)
• Elidel Consumer Information (Wolters Kluwer)
• Elidel Consumer Information (Cerner Multum)
• Elidel Topical Advanced Consumer Information (Micromedex)
• Elidel AHFS DI Monographs (ASHP)
• Pimecrolimus Consumer Information (Wolters Kluwer)
• Pimecrolimus topical Consumer Information (Cerner Multum)
• Pimecrolimus Topical Advanced Consumer Information (Micromedex)
• Pimecrolimus AHFS DI Monographs (ASHP)